Fontanet A L, Johnston D B, Walker A M, Rooney W, Thimasarn K, Sturchler D, Macdonald M, Hours M, Wirth D F
Epidemiology Department, Harvard School of Public Health, Boston, MA 02115.
Bull World Health Organ. 1993;71(3-4):377-83.
In order to assess the risk and predictors of mefloquine resistance we monitored a cohort of 113 patients in eastern Thailand who had been treated for uncomplicated falciparum malaria with a single dose of 15 mg/kg of the drug and followed up for 42 days. The overall treatment failure rate at day 42 was 59.1% (95% confidence interval (CI) = 50%, 68%) with only 2.7% of the patients being lost to follow-up. There were 6.4% RIII, 20.9% RII, 31.8% RI, and 40.9% sensitive responses, based on a modified WHO classification. A low haemoglobin level on the day of treatment and diarrhoea during the first two days after treatment were independent predictors of treatment failure. These findings remained statistically significant in a Cox proportional hazards model, after controlling for other baseline characteristics and adverse effects. Although a history of digestive disorders prior to treatment was associated with diarrhoea on day 2 (P = 0.024), it was in itself not a predictor of treatment failure (adjusted hazard ratio = 1.16; 95% CI = 0.35, 2.14). A total of 60 patients with an R response were hospitalized for 7 days to receive supervised treatment with quinine-tetracycline. Only three had a positive thick smear for asexual forms of Plasmodium falciparum 14 days later, and quinine-tetracycline therefore remains a good alternative treatment for mefloquine-resistant falciparum malaria.
为了评估甲氟喹耐药性的风险和预测因素,我们对泰国东部113例患者进行了监测,这些患者接受了单剂量15mg/kg的甲氟喹治疗非复杂性恶性疟,并随访了42天。42天时的总体治疗失败率为59.1%(95%置信区间(CI)=50%,68%),仅有2.7%的患者失访。根据世界卫生组织修改后的分类,有6.4%的RIII型、20.9%的RII型、31.8%的RI型和40.9%的敏感反应。治疗当天血红蛋白水平低以及治疗后前两天出现腹泻是治疗失败的独立预测因素。在控制了其他基线特征和不良反应后,这些发现在Cox比例风险模型中仍具有统计学意义。尽管治疗前有消化系统疾病史与第2天腹泻相关(P=0.024),但其本身并非治疗失败的预测因素(调整后风险比=1.16;95%CI=0.35,2.14)。共有60例R反应患者住院7天,接受奎宁-四环素的监督治疗。14天后,只有3例患者的恶性疟原虫无性体厚涂片呈阳性,因此奎宁-四环素仍然是耐甲氟喹恶性疟的一种良好替代治疗方法。